Lai K, Huang C, Li L, et al. - In this prospective interventional case series, researchers sought to assess the anatomical and functional responses in eyes with diabetic macular edema (DME) treated with ranibizumab under “1 + pro re nata (PRN)” regimen. The sample consisted of 69 patients (69 eyes) with DME treated with intravitreal injections of 0.5 mg ranibizumab followed by repeated injections as required. According to findings, intravitreal ranibizumab injections under “1 + PRN” regimen is a not only effective but also safe way to improve the visual acuity of DME patients. And older age, lower baseline best-corrected visual acuity (BCVA), vitreomacular traction, and ellipsoid zone disruption are predictors of final poor BCVA, while posterior vitreous detachment is a positive predictive factor for good final BCVA.